Article Information
History
- August 11, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Wren E. Michaels1,2,
- Cecilia Pena-Rasgado1,
- Rusudan Kotaria1,
- Robert J. Bridges1,* and
- Michelle L. Hastings1,*
- 1Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Science and Medicine, North Chicago, IL, 60064, United States of America
- 2School of Graduate and Postdoctoral Studies, Rosalind Franklin University of Science and Medicine, North Chicago, IL, 60064, United States of America
- ↵*To whom correspondence should be addressed. Tel: 1-847-578-8517; Fax: 1-847-578-3253; Email: michelle.hastings{at}rosalindfranklin.edu. Correspondence may also be addressed to robert.bridges{at}rosalindfranklin.edu.
Author Contributions: M.L.H. and R.J.B. initiated and supervised the study; W.E.M and M.L.H designed the experiments. W.E.M., R.K., and C.P. performed all the experiments. W.E.M and
Posted August 11, 2021.
Open reading frame correction using antisense oligonucleotides for the treatment of cystic fibrosis caused by CFTR-W1282X
